Chondrogard, 100 mg/ml 2 ml 10 pcs

High-molecular-weight mucopolysaccharide that affects metabolic processes in hyaline cartilage. It reduces degenerative changes in the cartilage of joints, accelerates the processes of its restoration, stimulates the synthesis of proteoglycans. Treatment with Hondrogard reduces pain and improves mobility of affected joints.

In the treatment of degenerative changes in joints with development of secondary synovitis positive effect can be observed within 2-3 weeks after the start of the drug administration: pain in the joints reduces, clinical manifestations of reactive synovitis disappear and the range of motion in the affected joints increases.

Therapeutic effect of Hondrogard lasts for a long time after the end of the course of treatment.

Indications

Degenerative-dystrophic diseases of the joints and spine:

Active ingredient

Composition

Active ingredient:

Chondroitin sulfate sodium – 100 mg.

Auxiliary substances:

benzyl alcohol – 9 mg,

sodium disulfite – 1 mg,

How to take, the dosage

The drug is administered intramuscularly 100 mg every other day.

If tolerated well, the dose is increased to 200 mg, starting with the fourth injection.

The course of treatment is 25-30 injections. If necessary, it is possible to repeat the course of treatment in 6 months.

For the formation of the bone callus the course of treatment is 3-4 weeks (10-14 injections every other day).

Interaction

It is possible to increase the effect of indirect anticoagulants, antiaggregants, fibrinolytic agents, which requires more frequent monitoring of blood clotting when used together.

Special Instructions

Pediatric use

There are currently no data on the efficacy and safety of chondroitin sulfate in children.

Contraindications

Side effects

Allergic reactions: skin itching, erythema, urticaria, dermatitis, hemorrhages at the injection site.

Pregnancy use

Contraindicated in pregnancy and lactation

Similarities